Edward Rosfjord

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Allan Wissner, Elsebe Overbeek, Marvin F. Reich et al. · Journal of Medicinal Chemistry · 2002 · 266 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

Matthew Sung, Xingzhi Tan, Bingwen Lu et al. · Molecular Cancer Therapeutics · 2017 · 208 citations

Medicine, Oncology, Pharmacology +17

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

Wenyan Zhong, Jeremy S. Myers, Fang Wang et al. · BMC Genomics · 2020 · 179 citations · Full text

Medicine, Immunology, Oncology +17

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

Michael D. Arensman, Xiaoran Yang, Danielle Leahy et al. · Proceedings of the National Academy of Sciences · 2019 · 171 citations · Full text

Medicine, Immunology, Oncology +17